Alchemia spending to boost fondaparinux profits
24 September, 2012 by Dylan Bushell-EmblingAlchemia (ASX:ACL) has revealed an extra $10 million investment to reduce production costs and maximise profits after acknowledging that market competition has delayed the profitability of generic fondaparinux in the US.
Government considering tightening innovation patents
24 September, 2012 by Tim DeanThe government has invited comment from the public on “tough new” amendments to intellectual property laws to tighten up innovation patents.
EndoBarrier on offer at two Australian clinics
24 September, 2012 by Dylan Bushell-EmblingGI Dynanics (ASX:GID) continues rollout of its EndoBarrier in Australia with it now offering the weight loss and diabetes treatment in two additional locations, St Vincent's Clinic and Macquarie University Hospital.
Avita's US trials may hold key to ReCell adoption
21 September, 2012 by Dylan Bushell-EmblingMajor US clinical trials of Avita Medical's (ASX:AVH) ReCell spray-on skin could provide the impetus needed to stimulate adoption of the technology in the medical community, a recent report suggests.
Patrys cleared for multiple myeloma trial
20 September, 2012 by Dylan Bushell-EmblingPatrys (ASX:PAB) plans to commence a phase I/IIb trial of anti-tumour antibody PAT-SM6 in Germany in Q4, after getting the go-ahead from regulators.
Presenting companies announced for major investment summit
20 September, 2012 by AusBiotechThe Australasian Life Science Investment Summit 2012, the largest investment event of its kind in the Southern Hemisphere will again be held in conjunction with Australia’s premier biotechnology industry conference, AusBiotech 2012. Companies selected to present at the event have been announced.
Government freeze on grants raises concern in biotech sector
19 September, 2012 by Tim DeanThe life science sector is increasingly concerned over an indefinite freeze which has been placed on federal government grants that support innovation. The freeze is not only preventing funds from flowing through to companies that have lodged applications, but the uncertainty over the nature and implications of the freeze is causing some to fear that certain grants may be cut.
Avexa still in the HIV game
19 September, 2012 by Dylan Bushell-EmblingAvexa is still working on developing next generation treatments for HIV following a turbulent couple of years, including the dumping of board in 2010 which ceased development of its lead HIV drug apcicitabine (ATC).
Immuron C. difficile study shows 100% survival
19 September, 2012 by Dylan Bushell-EmblingImmuron (ASX:IMC) has reported a 100% survival rate from animal trials of the C. difficile treatment candidate it is developing with Monash University.
Biota, Nabi amend merger terms to placate shareholder
18 September, 2012 by Dylan Bushell-EmblingBiota Holdings (ASX:BTA) and US-based Nabi Pharmaceuticals have amended the terms of their proposed merger, in a bid to placate Nabi shareholders seeking to block the deal.
Nexvet raises $2.5m to fund human-to-animal drugs
18 September, 2012 by Dylan Bushell-EmblingNexvet Biopharma has closed a $2.5 million seed financing round, after receiving an investment from the universities-led Trans Tasman Commercialisation Fund (TTCF).
New joint initiative to promote biotech and GM in agriculture
18 September, 2012 by Tim DeanA new industry group, the Agricultural Biotechnology Council of Australia (ABCA) has been formed to promote and encourage debate on the use of biotechnology and gene technology in agriculture in Australia.
Nominations called for Janssen 2012 Industry Excellence Awards
18 September, 2012 by AusBiotechJanssen & AusBiotech are pleased to announce that the Janssen 2012 Industry Excellence Awards, in three categories, are now open for nominations.
Bionomics acquires American cancer stem cell company
17 September, 2012 by Dylan Bushell-EmblingBionomics (ASX:BNO) has acquired US-based cancer stem cell drug development company Eclipse Therapeutics in a deal worth US$10 million ($9.5 million).
Priceline to stock Cellmid hair growth range
14 September, 2012 by Dylan Bushell-EmblingCellmid (ASX:CDY) subsidiary Advangen has now secured agreements with over 700 pharmacies including Priceline stores to stock its evolis line of hair growth products.
